Aleix Prat: Dual HER2 inhibition in Breast Cancer

Aleix Prat shared a post on X about a recent paper by Adrienne Waks et al. published in Nature Reviews Clinical Oncology.

“Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance”

Authors: Adrienne Waks, Olga Martínez-Sáez, Paolo Tarantino, Fara Braso-Maristany, Tomás Pascual, Javier Cortés, Sara Tolaney and Aleix Prat.

“Excited to share our latest review in Nature Reviews Clinical Oncology! 

We dive into the latest on dual HER2 inhibition in Breast Cancer—exploring synergy, patient selection, and resistance.

Big steps forward in personalized treatment for patients with HER2+ breast cancer, and more to come!

Check Figure 3 of the article!”

Source: Aleix Prat/X

More posts featuring Aleix Prat on oncodaily.com

Aleix Prat is the Director of the Cancer Institute at Hospital Clinic of Barcelona, Head of the Translational Genomics Group at IDIBAPS, and a Professor at the University of Barcelona.

He is also a Co-Founder of REVEAL GENOMICS, S.L. His work focuses on breast cancer genomics and the development of omics-based assays for clinical application. His expertise lies in breast cancer and gene expression profiling.